These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 22095647

  • 1. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
    Köhler W, Bucka C, Klingel R.
    J Clin Apher; 2011 Dec; 26(6):347-55. PubMed ID: 22095647
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment of myasthenia gravis with immunoadsorption.
    Haas M, Mayr N, Zeitlhofer J, Goldammer A, Derfler K.
    J Clin Apher; 2002 Dec; 17(2):84-7. PubMed ID: 12210711
    [Abstract] [Full Text] [Related]

  • 3. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
    Wagner S, Janzen RW, Mohs C, Pohlmann S, Klingel R, Grützmacher PW.
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
    [Abstract] [Full Text] [Related]

  • 4. Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis.
    Zeitler H, Ulrich-Merzenich G, Hoffmann L, Kornblum C, Schmidt S, Vetter H, Walger P.
    Artif Organs; 2006 Aug; 30(8):597-605. PubMed ID: 16911313
    [Abstract] [Full Text] [Related]

  • 5. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T.
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [Abstract] [Full Text] [Related]

  • 6. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
    Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C.
    Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040
    [Abstract] [Full Text] [Related]

  • 7. Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
    Ohkubo A, Okado T, Sakurasawa T, Maeda T, Itagaki A, Yamamoto H, Miyamoto S, Seshima H, Kurashima N, Mori T, Iimori S, Sohara E, Rai T, Uchida S, Naito S.
    Ther Apher Dial; 2019 Jun; 23(3):271-278. PubMed ID: 31025833
    [Abstract] [Full Text] [Related]

  • 8. Experience with extracorporeal elimination therapy in myasthenia gravis.
    Blaha M, Pitha J, Blaha V, Lanska M, Maly J, Filip S, Brndiar M, Langrova H.
    Transfus Apher Sci; 2011 Dec; 45(3):251-6. PubMed ID: 22018894
    [Abstract] [Full Text] [Related]

  • 9. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].
    Yeh JH, Chiu HC.
    J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565
    [Abstract] [Full Text] [Related]

  • 10. The treatment of severe forms of myasthenia gravis.
    Iani C, Caramia M, Morosetti M, Loberti M, Palmieri MG, Meloni C, Gallucci MT, Casciani CU, Bernardi G.
    Funct Neurol; 1998 Jun; 13(3):231-7. PubMed ID: 9800150
    [Abstract] [Full Text] [Related]

  • 11. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI, Grapsa EI, Kararizou E, Psimenou E, Lagguranis A, Dimopoulos A.
    Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
    [Abstract] [Full Text] [Related]

  • 12. A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy.
    Lieker I, Slowinski T, Harms L, Hahn K, Klehmet J.
    J Clin Apher; 2017 Dec; 32(6):486-493. PubMed ID: 28485075
    [Abstract] [Full Text] [Related]

  • 13. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
    Liu JF, Wang WX, Xue J, Zhao CB, You HZ, Lu JH, Gu Y.
    Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
    [Abstract] [Full Text] [Related]

  • 14. Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.
    Heigl F, Hettich R, Arendt R, Durner J, Koehler J, Mauch E.
    Atheroscler Suppl; 2013 Jan; 14(1):167-73. PubMed ID: 23357160
    [Abstract] [Full Text] [Related]

  • 15. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome.
    Okamiya S, Ogino M, Ogino Y, Irie S, Kanazawa N, Saito T, Sakai F.
    Ther Apher Dial; 2004 Jun; 8(3):248-53. PubMed ID: 15154879
    [Abstract] [Full Text] [Related]

  • 16. [Soluble adhesive molecules and cytokines in patients with myasthenia gravis treated with plasmapheresis].
    Tesar V, Jelínková E, Jirsa M, Bakosová N, Pit'ha V, Chábová V.
    Cas Lek Cesk; 1998 Nov 02; 137(21):654-9. PubMed ID: 9929930
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic apheresis in myasthenia gravis.
    Batocchi AP, Evoli A, Di Schino C, Tonali P.
    Ther Apher; 2000 Aug 02; 4(4):275-9. PubMed ID: 10975473
    [Abstract] [Full Text] [Related]

  • 18. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy.
    Psaridi-Linardaki L, Trakas N, Mamalaki A, Tzartos SJ.
    J Neuroimmunol; 2005 Feb 02; 159(1-2):183-91. PubMed ID: 15652418
    [Abstract] [Full Text] [Related]

  • 19. [Myasthenia gravis].
    Tanaka K.
    Nihon Rinsho; 2004 May 02; 62 Suppl 5():580-5. PubMed ID: 15197988
    [No Abstract] [Full Text] [Related]

  • 20. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis.
    Haupt WF, Rosenow F, van der Ven C, Birkmann C.
    Ther Apher; 2000 Jun 02; 4(3):195-7. PubMed ID: 10910018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.